We had the opportunity to dig deeper in to the commercial potential for AP1189 in nephrotic syndrome. As a result, we raise our base case valuation to SEK 17 per share.
Read more
News
October 2019
July 2019
SynAct Pharma AB (”SynAct”) utvecklar melanocortinreceptoragonisten AP1187 för behandling av aktiva inflammatoriska sjukdomar.
Read more